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Background: CELLFOOD™ (CF) is a nutraceutical non-addictive, non-invasive, and completely non-toxic unique proprietary
colloidal-ionic formula. Little is known about its effect on cancer cells in solid tumors. The aim of this study was to evaluate
the effect that CF has on different cancer cell lines and the mechanism by which the nutraceutical works.
Methods: The effect of CF on HFF (normal fibroblasts), Met5A (mesothelium), MSTO-211H, NCI-2452, Ist-Mes1,
MPP89, Ist-Mes2 (mesothelioma), M14 (melanoma), H1650, H1975 (lung cancer), SKRB3 (breast cancer), and HCT-116
(colorectal cancer) cell growth was tested by cell proliferation and clonogenic assay. Among all of them, MSTO-211 and
HCT-116 were analyzed for cell cycle by flow cytometry and western blot.
Results: All human cancer lines were suppressed on cell growth upon 1:200 CF treatment for 24 and 48 hours. Death
was not observed in HFF and Met5A cell lines. Cell cycle analysis showed an increased sub-G1 with reduction of G1 in
MSTO-211 and a cell cycle arrest of in G1 in HCT116. Activation of caspase-3 and cleavage of PARP confirmed an
apoptotic death for both cell lines. Increased expression levels of p53, p21, and p27, downregulation of c-myc
and Bcl-2, and inhibition of Akt activation were also found in CF-treated MSTO-211 and HCT-116 cells.
Conclusions: These findings ascertained an interaction between p53, c-myc, p21, p27, Bcl-2, PI3K/Akt pathway,
and CF-induced apoptosis in MSTO-211H and HCT-116 cells, suggesting that CF acts as an important regulator
of cell growth in human cancer cell lines. CF could be a useful nutraceutical intervention for prevention in colon
cancer and mesothelioma.
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CELLFOOD™ (CF) is a unique, proprietary concentrate
of 78 ionic minerals, 34 enzymes, 17 amino acids, electro-
lytes, and dissolved oxygen, held in a negatively-charged
suspension utilizing deuterium, the only non-radioactive
isotope of hydrogen. CF possesses antioxidant properties
which protect erythrocytes, lymphocytes, and biomole-
cules against free radical attacks, suggesting that it may be
an adjuvant intervention in the prevention and treatment* Correspondence: galati@ifo.it
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lated to oxidative stress [1]. The oral supplementation of
CF for a period of six months significantly improves fi-
bromyalgia symptoms and health-related quality of life
of fibromyalgic patients compared to placebo [2]. CF
treatment on leukemia cell lines induces cell death due
to apoptotic mechanisms and altering cell metabolism
through HIF-1α and GLUT-1 regulation [3]. However,
the anti-cancer activities and potential anti-cancer me-
chanisms of the nutraceutical in solid tumors have not
yet been elucidated.
Many physiological processes, including proper tissue
development and homeostasis, require a balance betweenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ate via a mitotic process determined by progression
through the cell cycle. Apoptosis (programmed cell death)
occurs in a wide variety of physiological settings, where its
role is to remove harmful, damaged or unwanted cells.
Apoptosis and cell proliferation are linked by cell-cycle
regulators and apoptotic stimuli that affect both processes.
A failure in regulating proliferation together with suppres-
sion of apoptosis are the minimal requirements for a cell
to become cancerous [4].
In the context of aberrant growth control, many im-
portant genes responsible for the genesis of various can-
cers have been discovered and the pathways through
which they act characterized. Two proteins involved
intimately in regulating cell proliferation are Akt and the
tumor suppressor p53 (p53). The protein serine/threo-
nine kinase Akt (also known as protein kinase B or PKB)
plays an important role in averting cell death. A diverse
range of physiological stimuli induce Akt kinase activity,
including many trophic factors which promote survival, at
least in part, through Akt activation via the phosphatidyli-
nositide 3′-OH kinase (PI3K) signaling cascade. Moreover,
induced Akt activity (p-AKT) (due to overexpression) is
sufficient to block apoptosis triggered by many death
stimuli [5]. p53 has an important protective role against
undesired cell proliferation. As such, p53 has been de-
scribed as the “guardian of the genome”. The p53 protein
is a transcription factor that normally inhibits cell growth
and stimulates cell death in response to myriad stressors,
including DNA damage (induced by either UV or chem-
ical agents such as hydrogen peroxide), oxidative stress,
and deregulated oncogene expression [6-10].
p53 activation is characterized by a drastic increase
and its rapid accumulation in stressed cells [11]. p53 is
a master gene regulator controlling diverse cellular path-
ways, by either activating or repressing downstream
genes. Among such genes, there is also the proto-
oncogene c-myc, which is negatively regulated by p53
[12]. The c-myc proto-oncogene encodes the c-myc
transcription factor, and was originally identified as the
cellular homologue to the viral oncogene (v-myc) of the
avian myelocytomatosis retrovirus [13,14]. More recently,
elevated or deregulated expression of c-myc has been
detected in a wide range of human cancers, and is often
associated with aggressive, poorly differentiated tumours
[15,16]. One of the key biological functions of c- myc is
its ability to promote cell-cycle progression [17-19] by
repressing genes as the cyclin-dependent kinase inhibi-
tors p21/WAF1 (p21) and p27Kip1 (p27), which are
involved in cell-cycle arrest [20-22]. Cell division relies
on the activation of cyclins, which bind to cyclin-
dependent kinases to induce cell-cycle progression
towards mitosis. Following anti-mitogenic signals, p21
and p27 bind to cyclin-dependent kinase complexes toinhibit their catalytic activity and induce cell-cycle
arrest [23].
Acceleration of tumorigenesis is observed when apop-
tosis is suppressed by overexpression of anti-apoptotic
proteins such as Bcl2 [24]. When anti-apoptotic Bcl-2
family members are overexpressed, the ratio of pro- and
anti-apoptotic Bcl-2 family members is disturbed and
apoptotic cell death can be prevented. Targeting the
anti-apoptotic Bcl-2 family of proteins can improve
apoptosis [25-27]. Apoptosis induction is arguably the
most potent defence against cancer growth. Evidence
suggests that certain chemopreventive agents can trigger
apoptosis in transformed cells in vivo and in vitro, which
appears to be associated with their effectiveness in
modulating the process of carcinogenesis.
In this study, we analyzed the effect of CF on 12 differ-
ent cell lines showing that the nutraceutical has anti-
cancer activity. Among all, colon cancer (HCT-116) and
mesothelioma (MSTO-211H) cell lines were the most
sensitive and were selected to study the action of CF on
cancer. The nutraceutical treatment induced death by
apoptosis, upregulation of p53 and downregulation of
c-myc, pAkt, and Bcl-2. Given the central role of these
molecular targets in cell proliferation and death, the




Breast (SKRB3), colorectal (HCT116), lung (H1650, H1975),
melanoma (M14), mesothelioma (MSTO-211H, NCI-2452,
Ist-Mes1, MPP89, Ist-Mes2) cancer cell lines, and fibroblast
(HFF) and mesothelio (MeT5A) cell lines were gradually
conditioned in DMEM/F12 + Glutamax (Invitrogen
Life Technologies, Paisley, UK) supplemented with
10% FBS and antibiotics and maintained at 37°C and
5% CO2.
Cellfood
CF (liquid) was kindly provided by Eurodream srl (La
Spezia, Italy) and stored at room temperature. CF was
diluted in phosphate buffered saline (PBS) and sterilized
using a 0.45 μm syringe-filter before use.
Cell growth assays
For cell growth experiments, cells were plated in quintu-
plicates in 96-well culture plates (Nunc, Milan, Italy) at
a density of 3 × 103 cells/well. 24 h later, the medium
was replaced with fresh growth medium containing
1:200, 1:400, 1:800, 1:1600 dilutions of CF. At 24 and
48 h of treatment, XTT labelling reagent (final concen-
tration 0.5 mg/ml) was added to each well, and the sam-
ples were incubated for an additional 4 h at 37°C. The
XTT assay (Cell proliferation Kit (XTT), Roche Molecular
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the yellow tetrazolium salt XTT to form an orange forma-
zan dye by metabolic active cells. Absorbance was mea-
sured at 492 nm with a reference wavelength at 650 nm
and the absorbance values of treated cells were presented
as a percentage of the absorbance versus non treated cells
(CNTRL). All experiments were repeated three times.
The anti-proliferative CF activity was assessed in mono-
layer cell culture conditions by plating cell lines in a T25
flask. After 24 h, CF (5 μl per ml of medium correspond-
ing to a 1:200 dilution) was added for the time indicated
in the experiments. Nothing else was added in CNTRL.
The expansion of cell culture proliferation was quantified
by manual cell counting. Experiments were repeated in
triplicate and media values were calculated.
Clonogenic assay
Five hundred viable cells per well (treated with CF and
CNTRL) were plated in a 35 mm dish and allowed to
grow in normal medium for 10-14 days and then stained
for 30 min at room temperature with a 6% glutaralde-
hyde, 0.5% crystal violet solution. Pictures were captured
digitally. All experiments were repeated at a minimum
twice for each cell line.
Flow cytometry
For cell cycle analyses, cells were fixed in 70% ethanol
and stored at -20°C over night. Fixed cells were treated
with 1 mg/ml RNase A (cat. 12091021, Invitrogen Life
Technologies, Paisley, UK) for 1 h at 37°C and DNA was
stained with Propidium Iodide (Sigma, St. Louis, MO,
USA). Samples were acquired with a Guava EasyCyte 8HT
flow cytometer (Merck Millipore Billerica, Massachusetts,
USA). Cell cycle distribution was shown.
Western blot analysis
Briefly, 25-50 μg of proteins extracted as described pre-
viously from cultured cells [21] were separated by SDS-
PAGE and transferred onto nitrocellulose membranes.
Membranes were blocked and blotted with relevant anti-
bodies: Bcl-2, p21, p27, p53, c-myc, caspase-3 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), p-AKT,
AKT, PARP (Cell Signaling Technology, Danvers, MA)
and γ-tubulina (Sigma, Saint Louis MO, USA). Goat
anti-mouse or rabbit or goat IgG horseradish peroxidase
conjugated secondary antibodies (1:3,000) (Bio-Rad Labora-
tories; Hercules, CA, USA) were visualized with enhanced
chemiluminescence reagent (ECL, Amersham-Pharmacia,
Uppsala, Sweden).
Results
CF induces death in human cancer cell lines
The antiproliferative effect of CF dilutions (1:200, 1:400,
1:800 and 1:1600) was assessed by Cell proliferation kitupon 24 and 48 h of treatment was tested on different
cell lines (Table 1). In all cancer cell lines CF had a
dose-response effect, in fact, the slight reduction in the
proliferative activity at 1:800 dilution increased and be-
came significant at 1:200 dilution. At this dilution dose,
no significant changes in the HFF and Met5A cell lines
were observed (Figure 1A). HCT-116 and MSTO-211
were the most sensitive to CF and for this reason they
have been selected for further studies. By manual count
of vital cells, the absence of inhibition of cell growth in
HFF and Met5A and the antiproliferative activity in
HCT-116 and MSTO-211 upon CF treatment were con-
firmed (Figure 1B) although with different percentages
compared to those obtained with the proliferation kit.
This shows that CF inhibits the proliferation of cancer
cell lines.
CF reduces the clonogenic survival of MSTO-211 and
HCT-116 cell lines
The effects of CF on HCT-116 and MSTO-211 cancer
cells and HFF and Met-5A normal cells in clonogenic
assays were evaluated. The clonogenic cell survival assay
determines the ability of a cell to proliferate indefinitely,
thereby retaining its reproductive ability to form a large
colony or a clone. This cell is then said to be clonogenic.
Single cells were plated and cultured for 10 days with
CF 1:200 (Figure 2). Colony formation was absent in
HCT-116 and MSTO-211, while HFF and Met-5A col-
ony yields were unaffected. This shows that CF select-
ively inhibits the ability of HCT-116 and MSTO-211to
grow into a colony.
CF induces apoptosis in HCT-116 and MSTO-211 cell lines
In order to confirm whether CF-induced growth inhib-
ition was due to apoptosis, CF-treated and untreated
Figure 1 Effects of CF on cancer and normal human cells. (A) Cells were cultured in the presence or absence of CF at the 1:200 dilution for
24 and 48 hours. Cell viability was measured using the XTT assay and expressed as% of inhibition of proliferation versus non treated cells (CNTRL).
Data are expressed as mean ± SD of at least three independent experiments. * p < 0.05 vs CNTRL. (B) HFF, Met5A, HCT-116 and MSTO cells were
treated with CF (5 μl/ml, corresponding to a 1:200 dilution) or not (CNTRL) for 24 and 48 hours, the graphs represent the vital cells number
measured by manual count. Data are expressed as mean ± SD of at least three independent experiments.
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cytometry. The G1 peak was increased in CF-treated
HCT-116 cells. The percentage of G1 peak in control
and CF-treated HCT-116 cells for 24 and 48 hours was32.8 ± 0.8, 39.0 ± 0.19 and 48.6 ± 1.5, respectively (Figure 3A).
The sub-G1 peak, which is indicator of apoptosis, was
raised following 24 and 48 hours of CF-treated MSTO-
211 cells. The percentage of this sub-G1 peak in control
Figure 2 HFF, Met5A, HCT116 and MSTO colony formation capacity upon CF treatment. Five hundred viable cells, pretreated for 48 h with
CF (1:200) and CNTRL, were allowed to grow in normal medium for 10-14 days and then stained by crystal violet solution. The image is
representative of three independent experiments.
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was 2.5 ± 0.03, 11.2 ± 1.0 and 17.8 ± 2.0, respectively
(Figure 3B), thereby suggesting apoptotic cell death.
Caspase-3 is expressed in cells as an inactive precursor
from which the subunits of the mature caspase-3 are
proteolytically generated during apoptosis. In our ex-
periments we used a mouse monoclonal antibody raised
against the full length caspase-3, so the reduction of the
expression of caspase-3 indicates apoptosis. Expression of
caspase-3 and cleavage of poly (ADPribose) polymerase
(PARP) (the substrate of caspase-3, an early index of apop-
tosis) were detected in western blot (Figure 3C,D) in
CF-treated HCT-116 and MSTO-211cells. These re-
sults show that CF induces apoptosis in HCT-116 and
MSTO-211 cells. These results show that CF induces
apoptosis in HCT-116 and MSTO-211 cells.CF induces apoptosis via upregulation of p53, p21 and
p27 and downregulation of c-myc
To clarify the detailed mechanisms underlying CF-induced
cell apoptosis, we detected the expression of apoptosis re-
lated proteins in CF-treated HCT-116 and MSTO-211cells
by western blot assay for the indicated time (Figure 4). We
found that the treatment with CF increased the expression
of p-53 and of the cell cycle-regulatory proteins p21 and
p27 as compared to CNTRL. p53 controls some genes in-
cluding c-myc. By investigating c-myc, we found that its ex-
pression is downregulated in CF-treated cells as compared
to the control, suggesting that p53 negatively regulates
c-myc. There are reports in the literature supporting
our findings showing that apoptosis could be induced
through downregulation of c-myc in curcumin treated
cancer cells [28-30]. These data indicate that p53, c-myc,
p21 and p27 play a decisive role in CF-induced apoptosis
of HCT-116 and MSTO-211 cells.CF induces apoptosis through inhibition of the PI3K/Akt
and Bcl-2 signaling pathway
We investigated the effect of CF on PI3K/Akt and Bcl-2
survival pathways. To test the status of Akt activation,
the phosphorylation of Akt was measured in HCT-116
and MSTO-211 by western blot analysis (Figure 5). A
high level of basal phosphorylated Akt (p-Akt) was
observed in both cells, and total Akt levels were found
to be almost equal in HCT-116 and MSTO-211 cells.
Consequently, we examined the protein expression and
phosphorylation level of p-Akt after CF treatment for the
indicated times in HCT-116 and MSTO-211 cells. The
levels of p-Akt significantly decreased following treatment
with CF while total Akt levels did not change (Figure 5).
Our experiments on Bcl-2 western blot assay in non-
treated and CF-treated HCT-116 and MSTO-211 cells
showed an evident decrease of Bcl-2 in CF-treated cells
(Figure 5). These data indicate that CF play a decisive role
in the survival pathway inhibition in HCT-116 and
MSTO-211 cells.Discussion
Cancer chemoprevention using natural or synthetic com-
pounds to prevent or suppress the development of cancer
is an area of active investigation. Many compounds be-
longing to diverse chemical classes have been identified as
potential chemopreventive agents, including dietary con-
stituents, nutraceuticals, naturally occurring phytochemi-
cals, and synthetic compounds. Because of their safety and
the fact that they are not perceived as ‘medicine’, natural
compounds have created high interest for their develop-
ment as chemopreventive agents that may find wide-
spread, long-term use in populations at normal risk.
Chemopreventive agents function by modulating pro-
cesses associated with xenobiotic biotransformation, with
Figure 3 Effects of CF on the HCT116 and MSTO cell-cycle progression and apoptosis. Cell cycle analysis after propidium iodide staining
was performed by flow cytometry in HCT-116 and MSTO cells untreated (CNTRL) or treated with CF (1:200) for 24 and 48 h (CF24 h and CF48 h).
The percentages of HCT-116 and MSTO cells in the different phases of cell cycle was reported in graph (A) and (B), respectively. Data are
expressed as mean ± SD of at least three independent experiments. Western blot of total lysates indicates that the CF activates caspase-3 and
PARP cleavage in HCT-116 (C) and MSTO (D) cells upon CF treatment (1:200) for 24 and 48 h versus the untreated control (C). γ tubulin was
examined as a loading control. The image represents three independent experiments.
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or with the promotion of a more differentiated phenotype
in target cells [31-34]. They induce apoptosis, inhibit cel-
lular proliferation, affect angiogenesis and cell metabolism
in various cancers, all of which are hindrances to tumor
growth [35-37].
It is know that cancer cells can not grow in a high
oxygen environment and that the prime cause of cancer
is the replacement of the normal oxygen respiration by
an anaerobic (without oxygen) cell respiration, focusing
the vital importance of oxygen [38]. Our body uses oxy-
gen to metabolize food and to eliminate toxins and
waste through oxidation. Cells undergo a variety of bio-
logical responses when placed in hypoxic conditions,
including switch in energy metabolism from oxidative
phosphorylation to glycolysis and activation of signaling
pathways that regulate proliferation, angiogenesis and
death. Cancer cells have adapted these pathways, allow-
ing tumours to survive and even grow under hypoxic
conditions, and tumour hypoxia is associated with poorprognosis and resistance to therapy [39,40]. In most
solid tumours, the resistance to cell death is a conse-
quence of the suppression of apoptosis (dependent on
mitochondrial energy production).
In this context, CELLFOOD™, the “physiological mo-
dulator” aimed to make available oxygen “on-demand”
with marked antioxidant effects [1,41,42], was inves-
tigated for apoptosis and cancer prevention. CF (also
known as Deutrosulfazyme™), is a nutraceutical supple-
ment whose constituents, including 78 trace elements
and minerals, 34 enzymes, 17 amino acids, electrolytes
and deuterium sulphate, are all naturally occurring sub-
stances which are essential to the body’s biochemical
functions. We tested the activity of CF on 12 different
cell lines, 2 normal and 10 cancerous. Our results showed
that CF reduced cell proliferation in a dose-dependent
manner in all the cancer cell lines used. Mesothelioma
(MSTO-211) and colon cancer (HCT-116) were the most
sensitive cell lines to the nutraceutical. Mesothelioma
(MM), which commonly originates from mesothelial cells
Figure 4 Expression of p53, c-myc, p21 and p27 in HCT-116 and MSTO cells. Cells were cultured in the absence or presence of CF (1:200)
for the indicated time and whole cell lysates were analyzed by western blot. Data representing three independent experiments with similar
results, indicate an upregulation of p53, p21 and p27 and a downregulation of c-myc in HCT-116 and MSTO cell upon CF treatment vs untreated
cells. γ tubulin was examined as a loading control.
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difficult to treat [43]. The number of MM patients is pre-
dicted to increase because of the long latency of the
disease and historical exposure to asbestos [44]. Colorectal
cancer is a major cause of morbidity and mortality
throughout the world [45]. CF suppresses cell growth by
apoptosis in MSTO-211 and HCT-116 cell lines. In
particular, we found that CF caused an increase of sub-G1
and a reduction of G1 in MSTO-211, and a cell cycle
arrest in G1 in HCT116. We speculated that CF-induced
proliferative block was irreversible due to the significant
increase in population with a sub-G1 and G1 DNAFigure 5 Effects of CF on the survival pathway in HCT-116 and MSTO
the indicated times and whole cell lysates were analyzed by western blot.
indicate a downregulation of Bcl-2 and p-AKT, whereas total AKT does no
untreated cells. γ tubulin was examined as a loading control.content (that are indicative of apoptosis) observed in the
treated cells as compared to the untreated ones.
Evidence of apoptosis in MSTO-211 and HCT-116
cells on CF treatment was observed in western blot. CF
induces apoptosis by a caspase-dependent pathway.
Among the caspase family members, caspase-3 is known
to be one of the key executioners of apoptosis because
caspase-3 activation causes the cleavage or degradation
of downstream important substrates, like PARP, which is
the hallmark of caspase-dependent apoptosis. In our ex-
periments, caspase-3 activation and PARP cleavage were
detected in CF-treated MSTO-211 and HCT-116. Thus,cells. Cells were cultured in the absence or presence of CF (1:200) for
Data representing three independent experiments with similar results,
t change in HCT-116 and MSTO treated with CF for 24 and 48 h vs
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observations. Nevertheless, to further explain the precise
mechanism of CF-induced apoptosis in cancer cells, we
examined the expression levels of p53, c-myc, Bcl-2,
pAkt and Akt. We identified p53 as the target of CF.
p53 is one of the most important tumour suppressor
genes, and it is frequently inactivated in various can-
cers. p53 modulates various cellular functions, such as
apoptosis and cell cycle arrest via transcriptional regu-
lation. Interestingly, wild-type p53 expression was de-
tected in 47% of colorectal adenocarcinomas [46], and
approximately 70–80% of mesothelioma cells, although
having the wild-type p53 gene, show a homologous de-
letion at the INK4A/ARF locus containing the p14ARF
and the p16INK4A genes, which consequently leads to
decreased p53 functions despite the wild-type genotype
[47]. MSTO-211 and HCT-116 cell lines endowed
wild-type p53 and CF treatment increased the expres-
sion level of p53.
Accumulating evidence indicates that c-myc has an
important function in cell proliferation and apoptosis
induction [48]. c-Myc expression is low in quiescent
normal cells whereas it is elevated in a broad range of
human cancers, such as the malignant pleural mesotheli-
oma, indicating its key role in tumour development [49].
Human malignant pleural mesothelioma shows elevated
c-myc expression and it is a transcription factor mediat-
ing cancer progression, highly overexpressed in 60% of
colorectal cancer, indicating that c-myc is a hallmark of
tumorigenesis [50-52]. Studies using conventional c-myc
transgenic mice, in which the oncogene is constitutively
expressed in a given cell type by means of a tissue-
specific promoter, have supported the view that dere-
gulated c-myc, as an initial event, is important for the
formation of certain cancers, albeit with a long latency
[24,53,54]. C-myc has also been reported to promote cell
cycle re-entry and proliferation through repression of
p21 and p27 expression [55]. In our experiments, CF in-
duced an upregulation of p21 and p27 thus, the suppres-
sion of c-myc expression by the nutraceutical may
render substantial therapeutic benefits in colorectal can-
cer and mesothelioma patients by inhibiting the driving
activities of c-myc in cell proliferation and cell cycle
progression.
The phosphatidylinositol 3-kinase (PI3K)/AKT signal-
ing pathway plays an important role in survival when
cells are exposed to various kinds of apoptotic stimuli
[56,57]. Recent reports have indicated that the activation
of Akt pathway is implicated in conferring resistance to
conventional chemotherapy and multiple chemothera-
peutic agents on cancer cells [58,59]. Akt is hyperacti-
vated in a wide range of human tumours as a result of
constitutive activation of growth receptors, mutation of
PI3K, and inactivation or loss of PTEN phosphatise [60].One mechanism by which Akt prevents apoptosis is
considered to proceed through phosphorylation and
inactivation of the pro-apoptotic protein and also induc-
tion of the anti-apoptotic Bcl-2 protein expression
[5,61]. The pro-survival Bcl-2 family members are piv-
otal regulators of apoptotic cell death; therefore, they are
considered as attractive targets for drug design [62,63].
Interestingly, we found p-AKT and Bcl-2 downregulation
in HCT-116 and MSTO-211 upon CF treatment, thus
leading us to believe that CF can be used for the preven-
tion of tumours and can possibly sensitize cancer cells
to standard therapy.
Conclusion
Taken together, these findings establish an interaction
between p53, c-myc, Bcl-2, p21, p27 and PI3K/Akt pathway
and CF-induced apoptosis in MSTO-211 and HCT-116
cells, which may improve prevention outcomes for meso-
thelioma and colon cancer. Given the central role of p53,
c-myc, Akt and Bcl2 in cell proliferation and death of many
cancers, together with the evidence obtained on MSTO-
211 and HCT-116 cell lines treated with CF, we believe in
the potential chemopreventive benefits of CF in human
cancers. Although further investigation is underway in our
laboratory, this present work suggests that CF can sensitize
cancer cells to standard therapy. In addition, as a nutri-
tional supplement, CF can improve the quality of life of
cancer patients undergoing antineoplastic therapy.
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